Reversing cellular aging: which startup is ahead?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
Life Biosciences is ahead in reversing cellular aging today, with NewLimit the only close challenger and Altos Labs still the field’s best-funded wildcard.
Life’s advantage is straightforward: it is the only startup directly testing partial cellular reprogramming in people. ER-100 has crossed the manufacturing, toxicology and regulatory barriers that every competing program still faces.
The lead is real but fragile. Life is roughly one regulatory stage ahead of NewLimit, which plans to begin human testing in 2027 and has enough capital to close the gap quickly.
NewLimit has built the fastest visible discovery operation in the field. Its advantage comes from repeatedly testing reprogramming payloads in old human cells and using the results to improve models that can transfer knowledge between liver, immune and vascular cells.
Life and NewLimit have made very different strategic bets. Life chose a narrow, measurable first organ that reduces delivery risk, while NewLimit chose the liver as a larger platform opportunity with a tougher safety and manufacturing burden.
Altos Labs cannot be ignored, but its enormous budget has not yet produced a publicly visible therapeutic candidate comparable with ER-100. Nearly $6 billion creates options; it does not prove that one of those options is ready to become a medicine.
Retro Biosciences is operationally stronger than most of the field, although its most advanced work currently tests autophagy and cell replacement rather than direct reprogramming. It belongs near the front of the longevity race, but slightly outside the core contest described here.
The animal evidence points in two directions. Rejuvenate Bio has published the boldest lifespan result, while Life has produced the more clinically useful bridge from restored function in mice to a defined human treatment.
No company has commercial validation yet. Regulatory clearance, pharmaceutical partnerships and large financing rounds show institutional confidence, but there is still no approved rejuvenation therapy or evidence that patients and insurers will accept its eventual price and risk.
The next ranking will be decided by clinical events, not another funding announcement. Early ER-100 safety data could strengthen Life’s lead, while a successful NewLimit trial launch would erase much of the current development-stage gap.
The field is therefore led by the company that has removed the most uncertainty, not the company with the largest laboratory or the highest valuation. Today that company is Life Biosciences, but NewLimit is moving fast enough to make the answer temporary.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Which startups are actually competing to reverse cellular aging?
The cellular-aging race currently has eight credible startups, although Life Biosciences, NewLimit and Altos Labs form the only group with both substantial resources and a serious claim to overall leadership.
We define this market narrowly. The companies included here are trying to restore younger cellular behavior through partial epigenetic reprogramming, rejuvenation genes or closely related interventions. They are attempting to change how old cells function, rather than merely measuring biological age or treating one downstream symptom of aging.
Retro Biosciences makes the list because tissue reprogramming remains part of its pipeline, even though its clinical-stage program uses autophagy. Rejuvenate Bio also qualifies because it has published direct partial-reprogramming results in naturally aged mice. Shift Bioscience, YouthBio Therapeutics and clock.health are much earlier, but each is building a distinct cellular-rejuvenation platform.
We exclude supplement companies, biological-age testing businesses, senolytic developers, plasma treatments, conventional stem-cell clinics and broad longevity holding companies without an identifiable cellular-rejuvenation program.
Turn Biotechnologies would previously have belonged in the comparison. Its mRNA-based ERA reprogramming platform was sold to Daewoong Pharmaceutical after an asset auction in May 2026, so Turn is no longer a clean standalone startup competitor. The sale is also a warning for the wider field: attractive science can still run out of financial runway before reaching patients.
Private-company funding totals vary because databases handle founder commitments, extensions and grants differently. We use disclosed rounds and clearly mark estimates.
| Startup | What it is developing | Funding publicly identified |
|---|---|---|
| Life Biosciences | Controlled OSK partial reprogramming, starting with optic-nerve diseases | Approximately $230M |
| NewLimit | AI-discovered reprogramming medicines, starting with liver aging | Approximately $760M |
| Altos Labs | Broad cellular rejuvenation and cellular-resilience research | Nearly $6B reported |
| Retro Biosciences | Autophagy, cell replacement and tissue-reprogramming therapies | At least $180M; latest round amount undisclosed |
| Rejuvenate Bio | AAV gene therapies, including partial OSK reprogramming | More than $16M in disclosed equity rounds |
| Shift Bioscience | AI-discovered rejuvenation targets and an siRNA program for liver fibrosis | $18M |
| YouthBio Therapeutics | Controlled partial reprogramming for Alzheimer’s disease | Undisclosed |
| clock.health | Genome-wide discovery of human rejuvenation genes | $5.3M |
Is any cellular-aging startup clearly ahead today?
Life Biosciences leads the cellular-aging race today, although NewLimit is now close enough that one strong clinical year could reverse the ranking.
Life’s lead comes from development stage. Its ER-100 program has entered an active Phase 1 study in people with glaucoma or non-arteritic anterior ischemic optic neuropathy. NewLimit has selected its first liver candidate, scaled production and publicly targeted human testing for 2027. Life is one full regulatory stage ahead.
Money points the other way. NewLimit has raised roughly 3.3 times as much capital as Life and recently reached a $3.1 billion valuation. Its discovery engine also covers liver cells, immune cells and vascular cells, while Life’s visible pipeline remains centered on the eye.
Altos Labs has vastly more money than either company, with The Wall Street Journal reporting that its total funding has approached $6 billion. Public evidence of a lead therapeutic candidate remains limited. Retro has already moved an aging-biology drug into human testing, although that drug stimulates autophagy rather than directly reprogramming cellular age.
Life leads clinical translation. NewLimit leads visible discovery velocity. Altos leads financial capacity, and Retro leads among the diversified longevity companies.
If you want more recent data on this point, please see our latest longevity market report.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Which cellular-aging startup is closest to proving rejuvenation in humans?
Life Biosciences is currently the only startup directly testing partial cellular reprogramming in people, giving it a clear lead in human evidence.
ER-100 uses an AAV2 vector to deliver three transcription factors, OCT4, SOX2 and KLF4, to retinal ganglion cells. Life intends the treatment to restore younger patterns of gene activity while allowing the cells to retain their normal identity.
The registered Phase 1 study plans to recruit 18 participants: 12 with open-angle glaucoma and six with NAION. Each participant receives a single dose and undergoes eye examinations, laboratory testing and long-term monitoring. The first six months provide the most intensive observation, while follow-up continues for five years because gene therapies can remain active for a long time.
NewLimit says its liver candidate is scheduled to enter human studies in 2027. YouthBio has completed an FDA INTERACT meeting for its Alzheimer’s candidate YB002, which gives the company early regulatory guidance but no authorization to begin dosing. Altos has not announced a registered cellular-rejuvenation trial, and Retro’s direct tissue-reprogramming programs remain preclinical.
The gap is simple. Life is collecting human safety data now. NewLimit is manufacturing material and completing the studies needed to request permission. YouthBio is still agreeing on the route toward that request. Everyone else is further back.
Has Life Biosciences proved that cellular reprogramming works?
Life Biosciences has proved that cellular reprogramming can reach a human trial. Proof that ER-100 safely restores human vision remains years away.
The current study is small, open label and primarily designed to detect safety problems. Eighteen participants cannot establish that partial reprogramming broadly reverses aging, and the study has no placebo group. Any improvement in vision would still need confirmation in larger controlled trials.
Life’s strongest evidence comes from the research behind ER-100. A Nature study published in 2020 found that OSK treatment helped retinal ganglion cells regenerate damaged axons and restored visual function in aged and glaucomatous mice. The work also linked those improvements to DNA-methylation changes associated with younger cells.
Life later reported related work in non-human primates, which helped support its regulatory package. For now, the company has strong mouse evidence, enough preclinical safety data to begin human testing and no human efficacy result yet.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Which startup has built the fastest cellular-reprogramming discovery engine?
NewLimit currently runs the fastest visible discovery operation in cellular reprogramming, at a scale none of its rivals publicly matches.
NewLimit combines computational predictions with large experiments in old human cells. Its models propose combinations of transcription factors, the laboratory tests those combinations, and the resulting data feed back into the next model. This lets the company search a biological space that would be impossible to explore one combination at a time.
In its 2025 review, NewLimit reported more than 600 payloads that made old cells display younger gene-expression patterns. Thirty-six also restored a youthful cellular function, and 16 improved disease-related outcomes in animal models. The company had progressed one of those payloads into a formal preclinical candidate. These are company-reported operating metrics, not independently verified benchmarks.
During the first two months of 2026, NewLimit reported 50 additional liver-cell payloads, 19 payloads that restored regulatory activity in T cells and a model upgrade that more than doubled discoveries per dollar. A few months later, the company said a generalized model achieved comparable predictions for vascular cells using one-third as much cell-specific data.
A model that transfers lessons between liver, immune and vascular cells could make each new program cheaper to launch. NewLimit still needs outside replication and clinical results, but no rival publicly reports comparable screening scale.
If you want more recent data on this point, please see our latest longevity market report.
Does NewLimit have better cellular-rejuvenation science than Life Biosciences?
Life Biosciences has the stronger evidence package today. NewLimit appears to have the broader platform and the higher long-term ceiling.
Life’s program follows a relatively complete path. Researchers first showed restored visual function in mice, then advanced the approach through additional animal studies, manufacturing, regulatory review and human dosing.
NewLimit has generated far more candidate breadth. Its lead liver payload reportedly helps old liver cells regenerate after injury, resist damage caused by alcohol and recover from harmful diets. The company has observed effects in humanized liver systems and animals, including benefits that lasted after the medicine had cleared from the body. These results carry more weight than a molecular clock alone because they measure whether old tissue performs better.
Life’s core mouse results have appeared in a leading peer-reviewed journal, and its development package has passed through FDA review. NewLimit provides unusually detailed updates, but its decisive liver results still come mainly from the company itself.
Life leads on evidence reliability. NewLimit leads on range and could move ahead by publishing the full liver dataset, reproducing the effect in larger animals and entering human trials.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Does Altos Labs’ huge budget make it the cellular-aging leader?
Altos Labs has the deepest resources in cellular rejuvenation, but Life Biosciences has converted far less money into much more visible clinical progress.
Altos launched with $3 billion in 2022. The Wall Street Journal has since reported that the company raised nearly twice that amount in total. That would give Altos close to eight times NewLimit’s capital and more than 25 times Life’s.
The company has used that money to recruit leading researchers, build institutes in the United States and the United Kingdom and combine experimental biology with computation. Altos is also developing AI world models that aim to predict how interventions will change cells, tissues and whole organisms before expensive experiments begin.
Its organization has gradually moved closer to drug development. Altos appointed Joan Mannick as chief medical officer and head of product development, a clear sign that the company wants to turn cellular-rejuvenation research into medicines.
The missing piece is a visible product. Altos has not publicly named a lead therapeutic candidate, announced an IND filing or registered a clinical trial comparable with Life’s eye program. It also publishes fewer program-level metrics than NewLimit.
The comparison with Life is stark. Life reached Phase 1 with roughly 4% of Altos’ reported capital and about 30% of NewLimit’s. It manufactured a clinical candidate, completed toxicology work, secured FDA clearance and began collecting human data.
Life benefited from a narrower strategy, licensed academic work and an accessible first organ. NewLimit and Altos are funding broader platforms that could eventually produce several therapies. Even allowing for those differences, Life has removed more product-development risk per dollar.
Rejuvenate Bio also stands out at a smaller scale. With little more than $16 million in disclosed equity funding, it produced a peer-reviewed lifespan study in old mice and secured animal-health partnerships.
Altos may have advanced work behind closed doors, but a competitive ranking has to use observable evidence. For now, its budget creates enormous future options without making it the current leader.
If you want more recent data on this point, please see our latest longevity market report.
Is Retro Biosciences really competing in cellular reprogramming?
Retro Biosciences is one of the strongest longevity startups now, although its direct cellular-reprogramming programs remain secondary to its clinical work in autophagy and cell replacement.
Retro is pursuing several ways to restore function in older people. Its pipeline includes an oral autophagy drug, induced pluripotent stem-cell therapies, protein engineering and tissue reprogramming. This diversified approach reduces the chance that one biological theory determines the fate of the entire company.
Its execution has been fast. Retro says RTR242 moved from indication selection to first-in-human dosing in 15 months. The drug is designed to restart autophagy, the process cells use to remove damaged components, and is being studied as a potential treatment for neurological decline. Retro has also built an internal cGMP cell-therapy manufacturing facility.
Investors rewarded that progress with a new financing round announced in May 2026 at a $1.8 billion pre-money valuation. Retro belongs just behind the three main leaders because its development organization is already moving at clinical speed, even though its tissue-reprogramming candidates remain early.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Which startup has the best animal evidence for reversing cellular aging?
Life Biosciences has the most clinically useful animal evidence, while Rejuvenate Bio has produced the field’s boldest published lifespan result.
Rejuvenate Bio treated 124-week-old male mice with an inducible AAV9 therapy carrying OSK. The study reported a 109% increase in median remaining lifespan and an improvement in frailty.
The treatment did not double lifespan from birth. It roughly doubled the short period these extremely old mice had left, and the experiment involved a modest group of male animals.
Life’s mouse results translate more directly into a drug program. OSK treatment regenerated optic-nerve axons and improved visual function in models of aging and glaucoma. The company could then use a local injection, a defined patient group and measurable eye endpoints to design a clinical trial.
NewLimit has lately reported that older animals receiving its liver candidate recovered better from injury and behaved more like young animals after alcohol exposure. The full studies have not yet appeared in a peer-reviewed paper.
Rejuvenate leads on published lifespan extension. Life leads on the bridge from animal evidence to human treatment.
Has Life Biosciences chosen the smartest first organ for cellular reprogramming?
Life Biosciences chose the eye because it offers the safest and most measurable first test of cellular reprogramming, giving the company a real delivery advantage.
Reprogramming treatments must reach the right cells, activate strongly enough to change them and stop before the cells lose their identity. Delivering that level of control throughout the body remains one of the field’s hardest unsolved problems. A Nature Communications review concluded that tissue-specific approaches are more likely to work clinically in the near term because current delivery systems struggle with efficiency and organ specificity.
The eye reduces several of those difficulties. Doctors can inject a small quantity directly into one organ, limiting exposure elsewhere. They can repeatedly examine the retina and optic nerve through imaging, visual-field tests and electrical measurements. The treatment also targets retinal ganglion cells, a defined cell population whose degeneration causes permanent vision loss.
NewLimit has chosen the liver, a larger opportunity with a higher safety burden. Lipid nanoparticles and RNA medicines already tend to accumulate there, but NewLimit will need to control dose, immune response, abnormal growth and off-target delivery across a much larger organ.
Life chose the better first clinical target. NewLimit chose the larger platform opportunity.
If you want more recent data on this point, please see our latest longevity market report.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Which cellular-reprogramming startup has the safest approach?
Life Biosciences has the most thoroughly tested safety design today, while Shift Bioscience is developing the clearest alternative to multi-factor reprogramming.
Traditional reprogramming uses OCT4, SOX2, KLF4 and c-MYC. Prolonged or poorly controlled expression can push mature cells toward pluripotency, remove their normal identity and create tumors. The safety challenge is finding enough reprogramming to restore function while stopping well before that dangerous point.
Life removes c-MYC, restricts administration to the eye and controls OSK expression through a doxycycline-sensitive system. Regulators reviewed the company’s manufacturing, toxicology and animal package before allowing ER-100 into Phase 1. That clearance supports a cautious first human test; it does not guarantee that the treatment will prove safe.
Shift’s earlier SB000 research identified a single gene that lowered molecular-age measurements in fibroblasts and skin cells without activating pluripotency in the reported experiments. Its current lead program, SB101, uses siRNA against a fibrosis pathway and could offer a more familiar, adjustable route than permanent gene delivery. Both programs still need independent and in-vivo validation.
NewLimit also uses transient RNA-based payloads and says its liver candidate produced no tumors or liver toxicity in animals even at high doses. The evidence still comes from company reports.
Has any cellular-aging startup found real commercial demand?
No cellular-aging startup has commercial validation yet because the category still has no approved rejuvenation therapy, recurring drug revenue or repeat customer demand.
The strongest evidence available today comes from regulators, pharmaceutical partners and investors willing to fund clinical development.
Life has the clearest regulatory validation. The FDA allowed ER-100 to proceed into human testing, and the company then closed an $80 million Series D to finance the study and extend its operating runway into the second half of 2027. Investors were funding an active clinical program rather than a laboratory concept.
NewLimit has the strongest capital-market endorsement. Its $435 million Series C included Founders Fund, Thrive Capital, Greenoaks, Kleiner Perkins and Eli Lilly Ventures. The round valued a pre-revenue company at $3.1 billion, reflecting unusually strong confidence in its discovery platform and first liver candidate.
Rejuvenate Bio has secured a more concrete industry relationship. Merck Animal Health participated in its latest $6 million financing and entered a research collaboration around a veterinary gene-therapy program. That agreement gives Rejuvenate a credible route to collect data in companion animals, although it says little about demand for human cellular rejuvenation.
YouthBio’s FDA INTERACT meeting provides useful guidance for YB002. Retro’s active trial and regulatory interactions validate its development team. Altos’ funding validates the quality of its scientists and ambition.
None of these events shows that patients, hospitals or insurers will pay for cellular rejuvenation. Commercial leadership begins only when a treatment produces enough clinical benefit to justify its price and risk.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Which cellular-aging startup can manufacture at clinical scale?
Life Biosciences has already manufactured a reprogramming therapy suitable for human use, while NewLimit now shows the strongest scaling momentum.
Life had to produce, test and release clinical-grade ER-100 before administering it in Phase 1. AAV products require consistent vector identity, purity, potency and sterility. The small quantity needed for an eye injection makes the program more manageable than a systemic gene therapy, but the manufacturing threshold is still real.
NewLimit started large-scale manufacturing of its first candidate early in 2026. In its latest update, the company reported producing batches more than 120 times larger than before, enough to support pivotal preclinical studies. It explained that discovery experiments require less than one milligram, toxicology studies need more than 100 milligrams and the clinical trial will require over 1,000 milligrams.
The company has also built a potency assay that measures whether each batch produces the intended biological effect in cells. That is important for a reprogramming medicine because checking the amount of RNA or the size of a lipid particle cannot show whether the payload actually rejuvenates its target cell.
Retro has the strongest internal infrastructure outside the two leaders. Its in-house cGMP facility supports cell therapies, and the company has already shown that it can move an oral drug into human testing quickly. Tissue-reprogramming products will still require their own manufacturing process.
Altos can afford virtually any external or internal manufacturing strategy, but its readiness cannot be judged without a disclosed candidate.
| Startup | Manufacturing evidence currently visible | Our assessment |
|---|---|---|
| Life Biosciences | Clinical-grade AAV2 product released and used in Phase 1 | Most validated today, with modest quantities required for eye delivery |
| NewLimit | More than 120-fold batch scale-up, potency testing and pivotal-study supply | Fastest current scaling progress |
| Retro Biosciences | Internal cGMP cell-therapy facility and active clinical operations | Strong infrastructure across several modalities |
| Rejuvenate Bio | Repeated AAV development for animal and research programs | Credible specialist capability |
| Altos Labs | Vast capital but no disclosed clinical product | Capacity likely available; readiness cannot be measured |
| Shift, YouthBio and clock.health | Discovery or early preclinical work | Clinical manufacturing has not been demonstrated |
Which cellular-aging startup has the hardest advantage to copy?
NewLimit is building the strongest long-term data advantage, Life Biosciences owns the most valuable clinical head start, and Shift Bioscience has the best chance of disrupting both with a simpler drug.
NewLimit’s discovery loop could become a compounding moat. Every tested payload adds proprietary information about how specific combinations affect old human liver, immune or vascular cells. Better models then guide the next experiments, creating more useful data.
The latest cross-cell results strengthen that argument. NewLimit says its generalized model reached similar vascular-cell performance with three times less cell-specific data. If the effect holds across additional tissues, new programs should need fewer experiments and less money.
Life’s advantage comes from experience that cannot be compressed into a software model. The company has learned how to manufacture ER-100, prepare a regulatory submission, run an ocular gene-therapy study and monitor patients over time.
Shift offers the clearest upset scenario. Its present SB101 strategy uses a single siRNA target rather than a combination of pluripotency factors. A successful single-target drug could simplify delivery, dosing, manufacturing and regulatory review.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
Which cellular-aging startup has gained the most momentum lately?
Life Biosciences achieved the biggest single leap by entering human testing, while NewLimit has advanced faster across discovery, manufacturing, hiring and financing.
Life compressed several linked milestones into the first half of 2026: FDA clearance, trial initiation, new financing and patient dosing. Together, they moved partial cellular reprogramming from animal experiments into clinical medicine.
NewLimit’s progress covered more ground. The company selected its first candidate earlier than originally expected, doubled discovery speed through AI, added a vascular program, scaled manufacturing more than 120-fold and raised enough capital to support several years of development. It is also recruiting clinical-development and technical-operations staff, showing that the company is changing from a research lab into a drug developer.
Retro strengthened its position with a new financing at a $1.8 billion pre-money valuation and continued planning additional first-in-human milestones. Rejuvenate Bio added Merck Animal Health as both an investor and research partner. Shift sharpened its commercial direction around SB101 and liver fibrosis.
Altos continues to build scientific and product-development capacity, yet recent public disclosures still lack a candidate-level milestone capable of matching Life or NewLimit.
| Startup | Most important recent progress | How it affects the race |
|---|---|---|
| Life Biosciences | ER-100 entered active Phase 1 testing | Gives Life the field’s first human lead |
| NewLimit | Candidate development, 120-fold manufacturing scale-up and a $435M financing | Makes a 2027 clinical challenge credible |
| Retro Biosciences | New financing at a $1.8B pre-money valuation and continuing clinical expansion | Strengthens Retro as a diversified longevity biotech |
| Rejuvenate Bio | $6M financing and Merck Animal Health collaboration | Adds a credible veterinary validation route |
| Shift Bioscience | Current product strategy centered on SB101 for liver fibrosis | Provides a clearer path from discovery platform to drug |
| Altos Labs | Continued hiring in computation and product development | Builds long-term capacity without clarifying clinical timing |
What could change the cellular-aging startup ranking next?
Human safety data from Life Biosciences and clinical entry from NewLimit will determine the next leader far more than another funding round or mouse experiment.
The first major event will be ER-100’s early safety record. Clean results would strengthen Life’s lead. Serious inflammation, unexpected cell changes or vector-related toxicity would weaken Life and could hurt confidence in OSK-based treatments more broadly.
The second event is NewLimit’s planned clinical start. Entering human trials in 2027 would close much of the current stage gap, especially if its transient RNA medicine avoids permanent genetic expression. A delay would expose the difference between rapid discovery and the slower work of toxicology, manufacturing and regulation.
A disclosed Altos candidate could also change the ranking quickly. Convincing large-animal evidence or an announced regulatory filing would push Altos into the top group. Strong animal results from Shift could create another route around Yamanaka-factor safety concerns.
Ultimately, efficacy will decide the race. A treatment that safely improves vision, liver function, fibrosis or cognition will move ahead regardless of which company has raised the most money.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Which startups are actually ahead in reversing cellular aging?
Life Biosciences is ahead overall now, NewLimit is the only close challenger, and Altos Labs remains the powerful wildcard that has yet to show its hand.
Life holds first place because it has removed the largest amount of uncertainty. Its underlying approach restored function in animal models, survived manufacturing and toxicology work, passed FDA review and entered a human study. The company still has no human efficacy result, but every competitor carries that same uncertainty plus earlier development risks.
NewLimit ranks second by a wide margin over the rest. Its discovery volume, functional liver results, manufacturing progress and recent financing show that it has moved beyond exploratory research. NewLimit could overtake Life if it starts human trials as planned with a transient, scalable therapy and strong published preclinical evidence.
Altos ranks third because its resources and scientific team remain impossible to dismiss. We place it behind two much smaller companies because the public pipeline is still difficult to evaluate. Capital creates options; it does not show which option can become a medicine.
Retro ranks fourth. Its clinical speed, manufacturing infrastructure and diversified pipeline make it more operationally mature than most of the field. The gap comes from category fit: Retro’s advanced programs currently validate autophagy and cell replacement more than direct cellular reprogramming.
Rejuvenate Bio ranks fifth through its published lifespan experiment and pragmatic animal-health strategy. Shift moves into sixth with a clearer current product path and a potentially safer single-target approach. YouthBio follows because its Alzheimer’s program has received early FDA feedback but faces a difficult brain-delivery problem. clock.health remains last because its rejuvenation atlas is interesting discovery work without a defined therapeutic program at comparable maturity.
The competitive gap at the top is meaningful but fragile. Life is one clinical stage ahead. NewLimit has more than three times the capital, a broader platform and the fastest visible operating pace. A clean Life safety readout would widen the gap; a successful NewLimit clinical launch could nearly erase it.
| Rank | Startup | Why it ranks here |
|---|---|---|
| 1 | Life Biosciences | Strongest complete chain from peer-reviewed animal evidence to regulated human testing |
| 2 | NewLimit | Best discovery engine, fastest recent acceleration and a credible near-term clinical candidate |
| 3 | Altos Labs | Unmatched capital and scientific depth, with too little visible product evidence |
| 4 | Retro Biosciences | Proven clinical-development speed and broad infrastructure, while direct reprogramming remains early |
| 5 | Rejuvenate Bio | Strong published mouse result and a practical animal-health development route |
| 6 | Shift Bioscience | Differentiated single-target strategy and a clearer liver-fibrosis product path |
| 7 | YouthBio Therapeutics | Focused Alzheimer’s program with early regulatory engagement but major delivery risk |
| 8 | clock.health | Large rejuvenation-gene discovery dataset without a mature therapeutic candidate |
If you want more recent data on this point, please see our latest longevity market report.
OUR METHODOLOGY
This analysis asks which startup is furthest ahead in reversing cellular aging. We define the market narrowly around companies trying to restore younger cellular behavior through partial epigenetic reprogramming, rejuvenation genes or closely related interventions.
We included companies with an identifiable cellular-rejuvenation program and excluded biological-age testing, supplements, senolytics, plasma treatments, conventional stem-cell clinics and broad longevity companies without a specific reprogramming or rejuvenation platform.
We looked at clinical progress, scientific evidence, discovery output, manufacturing readiness, regulatory execution, funding, partnerships and platform breadth. The final ranking was not produced by a formula: we compared each dimension separately and then judged which companies had removed the most important development risks.
We prioritized observable execution. Human dosing, regulatory clearance, peer-reviewed functional results and released clinical-grade products carried more weight than funding totals, valuations, hiring plans or molecular-age measurements on their own.
We used functional outcomes to separate convincing rejuvenation results from weaker proxy evidence. Restored vision, improved tissue recovery, reduced frailty and longer remaining lifespan were treated as more informative than changes in gene expression or epigenetic clocks without a corresponding improvement in cell or tissue performance.
Company-reported discovery and animal results were used as operating evidence, especially where startups disclosed payload counts, manufacturing scale or candidate progress. We distinguished those updates from peer-reviewed findings and regulatory records rather than treating every claim as equally established.
Funding totals reflect publicly disclosed rounds and clearly identified financing commitments. Turn Biotechnologies was excluded from the final competitor ranking because its ERA reprogramming assets were sold to Daewoong Pharmaceutical after the company’s May 2026 asset auction.
Key sources included ClinicalTrials.gov for the registered ER-100 study, Life Biosciences, NewLimit, Altos Labs, Retro Biosciences, Rejuvenate Bio, Shift Bioscience, YouthBio Therapeutics and clock.health for company pipelines and technical updates.
Independent anchors included the 2020 Nature study on OSK-mediated vision restoration, the FDA’s description of the INTERACT process, The Wall Street Journal’s reporting on Altos Labs funding, Merck Animal Health’s collaboration materials and PubMed-indexed research cited throughout the analysis.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across Europe, Asia, North America, Africa, and South America in the longevity market
Related blog posts
- Who is closest to reversing aging?
- Who is closest to a real anti-aging drug today?
- Has any longevity drug worked yet?
